# MultiplexDX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/multiplexdx

- Industry: Biotechnology
- Headquarters: Gaithersburg, US
- Website: www.multiplexdx.com
- Total disclosed funding: $0.5M
- Latest round: Seed (Jun 1, 2016)
- Investors on record: 1

## About

MultiplexDX Inc. is a biotechnology company focused on developing advanced diagnostic solutions, particularly for breast cancer research, enhancing diagnostic accuracy through its innovative products.Founded in 2015 and headquartered in Gaithersburg, US, MultiplexDX Inc. specializes in diagnostic innovations. The company was established by Pavol Cekan, who also serves as CEO. Through three investment deals, the company raised a total of EUR 1.20 mn in its latest round on 25 September 2018, with participation from Acorus Networks SAS and Neulogy Ventures.MultiplexDX, Inc. specializes in the development and provision of advanced diagnostic solutions, primarily focused on breast cancer research and diagnostics. The company's flagship offerings include high-quality fluorescently labeled DNA and RNA oligonucleotides, as well as custom 3'-adapters designed for small RNA library preparations. These products play a critical role in enhancing the accuracy of diagnostic tests, which directly influences treatment pathways and improves patient outcomes. MultiplexDX serves a diverse clientele, including research institutions and laboratories engaged in high-throughput screening and molecular biology applications across Europe. The company’s products are utilized by professionals in the life sciences sector who require reliable, high-performance reagents, with a notable presence in markets such as Germany, the United Kingdom, and France.MultiplexDX generates revenue through direct sales of its diagnostic products, which are marketed primarily to research institutions and laboratories in Europe. The company engages in business-to-business transactions, where clients place orders for specific quantities of oligonucleotides and 3'-adapters tailored to their research needs. These products are supplied at competitive prices, reflecting the quality and reliability that MultiplexDX is known for in the industry. Regular transactions may involve bulk orders, subscription agreements for ongoing supply, or partnerships with research organizations, ensuring a steady revenue stream. The company’s revenue structure is founded on the demand for its flagship products, which are integral to high-throughput screening and RNA research applications.MultiplexDX plans to leverage its recent funding of EUR 1.20 mn, raised in September 2018, to further develop its product line, particularly in breast cancer diagnostics. The company is focused on expanding its market presence in Germany, the United Kingdom, and France by the end of 2023. The funding will support the launch of new diagnostic products aimed at enhancing precision in cancer detection and improving research capabilities for its clients.

## Funding rounds

- Seed, Jun 1, 2016, $0.5M — Neulogy Ventures

## Investors

- Neulogy Ventures (https://capitalatlas.ai/funds/neulogy-ventures) — Seed